Estimated primary-completion dates from ClinicalTrials.gov and expected earnings reports. These are registry estimates, never confirmed readout dates; they can move as trials progress.
Filings, regulator decisions, scientific presentations, topline results and licensing deals, each from a dated source. When a source gives only the month, the month is shown.
Recent
9 October 2026Filing submittedApatinibRivoceranib NDA resubmitted to the FDA after July 2026 CRL
Educational data tool. Figures are sourced from company filings and press releases: see each row's filing link. Share prices are end-of-day closes, delayed by 24 hours.